ArticleCureus2025
Efficacy and Safety of Folisurge, a Biosimilar Recombinant Follicle-Stimulating Hormone, Versus Gonal-F in Assisted Reproductive Technology Practice in India: A Real-World Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study was conducted to compare the efficacy and safety of Folisurge, a biosimilar recombinant follicle-stimulating hormone (r-FSH), with Gonal-f, an innovator r-FSH, in patients undergoing assisted reproductive technology (ART).
methodsIn this non-interventional, investigator-initiated, real-world, retrospective study, females aged 21-40 years with a body mass index (BMI) ranging between 17 and 34.9 kg/m
resultsA total of 3090 women were included, out of which 1210 and 1880 received Folisurge and Gonal-f, respectively. The baseline demographics were comparable in the two groups. The mean antral follicle count (AFC) was significantly higher in the Folisurge vs. the Gonal-f group (23.8 vs. 20.6, p < 0.001). Also, the mean (SD) number of oocytes retrieved was significantly higher in the Folisurge vs. the Gonal-f group (18.1 (9.4) vs. 15.5 (8.3), p < 0.001). The mean (SD) number of MII oocytes retrieved with Folisurge was significantly higher than Gonal-f (13 (7.5) vs. 10.9 (6.6), p < 0.001). Also, the mean (SD) number of embryos formed was also higher in the Folisurge vs. the Gonal-f group (4.9 (4.1) vs. 4.7 (4.1), p = 0.022). The serum β-hCG positive rate was similar between the two groups (75.5% vs. 76.2%, p = 0.667). No major safety concerns were observed in the study.
conclusionFolisurge was comparable to Gonal-f in terms of serum β-hCG positive rate. The higher yield of oocytes and embryos in the Folisurge group should be interpreted in the context of its higher baseline AFC, which may have influenced these results. No major safety concerns were observed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.